Evaluation of Recombinant SAG1 Protein for Detection of *Toxoplasma gondii* Specific Immunoglobulin M by ELISA Test

N Jalallou¹, M Bandehpour², H Khazan³, A Haghighi³, *B Kazemi², ⁴

¹. Dept. of Medical Laboratory Science, School of Medicine, Army Medical Science University, Tehran, Iran
². Dept. of Biotechnology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
³. Dept. of Medical Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
⁴. Cellular and Molecular Biology Research Centers, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding author: Tel.: 0098 21 22439956, Email: bahram_14@yahoo.com, kazemi@sbmu.ac.ir

(Received 19 Mar 2012; accepted 15 Sep 2012)

ABSTRACT

**Background:** Toxoplasmosis is a serious disease in immunocompromised patients and pregnant women. Differentiation of acute and chronic infection is a major challenge in serodiagnosis of the disease. Since the aim of this study was to assess the diagnostic utility of recombinant SAG1 (rec-SAG1) for the detection of *Toxoplasma*-specific IgM antibodies in human sera, by an enzyme-linked immunosorbent assay (ELISA).

**Methods:** The purified recombinant protein SAG1 was applied in house ELISA test and the ability of it in binding to specific immunoglobulin M in 30 serum samples of acute infected patients was evaluated. The results obtained by assays with the recombinant SAG1 and standard commercial assays were compared.

**Result:** The sensitivity and specificity of in house ELISA compared to a standard commercial ELISA (com-ELISA) were 80% and 90%, respectively.

**Conclusion:** It was concluded that the rec-SAG1 could be an alternative marker for detection of anti *Toxoplasma*-specific IgM and diagnosis of acute infection.

**Keywords:** *Toxoplasma gondii*, Recombinant SAG1, IgM, ELISA
Introduction

Toxoplasma gondii is an opportunistic pathogen, which is generally asymptomatic in immunocompetent individuals. In contrast, parasite transmission during pregnancy can result in serious complications in fetal and neonatal (1). Also, toxoplastic encephalitis has been reported as a major cause of death in HIV-AIDS patients (2). Therefore, using of specific and sensitive methods could be an important step towards treatment and prevention of toxoplasmosis. At present the existing tests have differ ability for detection of IgG and IgM antibodies in sera of infected persons; in most cases, they are based on soluble antigens of tachyzoite (3, 4). Owing to the intrinsic restrictions of such antigens that was applied in serological tests, purified recombinant antigens could be an appropriate choice for detection of serum antibodies (5). The surface antigens of the parasite are taken into consideration by most of the researchers, as they are the key of successful parasite entry into host cells (6). Among them, the surface antigen-1 (SAG-1) is a 30kD glycoprotein and could be detected in tachyzoite and sporozoite stages; has been proven to be a superior antigen for improving diagnostic tests or subunit vaccines (7).

One of the most important serological markers to identify acute toxoplasmosis is the presence of Toxoplasma-specific IgM antibodies and SAG1 is one of the first antigens recognized by IgM during acute infection (8). In spite of the absolute advantages of using recombinant SAG-1 in an enzyme-linked immunosorbent assay (ELISA) to detect Toxoplasma-specific IgG antibodies in human sera, there are different results about usefulness of this antigen in recognition of IgM specific antibodies (5,9). Therefore the objective of this study was to evaluate the diagnostic utility of recombinant ELISA in compression to commercial ELISA for detection of Toxoplasma-specific IgM antibodies in human serum samples.

Materials and Methods

Recombinant antigen

SAG-1 gene (accession number EF 140712) was used (10). The construction of the recombinant expression plasmid pET32a- SAG1 was carried out based on previous author publication (11). Briefly, the recombinant antigen was expressed in BL21 (DE3) pLysS competent bacterial cells as a fusion protein supplied with an N-terminal thioredoxin coding sequence and 6 His X6 tags at both ends. Then, rec-SAG1 was purified by Ni-affinity chromatography, the eluted fraction was dialyzed against PBS and the protein concentration was measured by Biophotometer.

Serum Samples

A total number of 70 serum samples were used in this study. Sera were collected from diagnostic laboratories in Tehran and the Parasitology Department of Tehran University of Medical Sciences. Despite evaluation of sera in origin laboratories by different methods (IFA, ELFA, Chemiluminescence and ELISA) all of them were reexamined with a commercial ELISA kit (Euroimmun, Lubeck, Germany). Only serum samples that were positive or negative in both steps were used in the recombinant ELISA (rec-ELISA).

Rec- ELISA

The optimum antigen, serum concentration and conjugate dilution were determined by initial checkerboard titration. Purified rec- SAG-1 was diluted to the optimized concentration of 6 µg per ml in 50 mM carbonate- bicarbonate buffer (pH 9.6). One hundred µl of diluted r-SAG1 was coated to separate wells of flat bottomed polystyrene microplates (Greiner Bio One, Germany) at 4ºC overnight. Wells were washed three times (PBS, pH 7.2, 0.05% Tween 20), and then blocked for 2 hours at room temperature with

Available at: http://ijpa.tums.ac.ir
blocking solution (1% BSA and 0.05% Tween 20 in PBS). After repetition of washing stage, 100 µl of serum samples diluted 1:100 in blocking solution, were added into the wells and stored for 1.5 hours at room temperature. For each serum sample, the assay was done in duplicate, and average values were calculated. After three times washing, bound human IgM was detected by adding 100 µl Polyclonal goat anti- human IgM horseradish peroxidase conjugate (Abcam), 1:10000 in blocking solution to each well. The plates were incubated for one hour at room temperature, and then were washed like before. One hundred µl of the Ortho phenylene Diamine (OPD; Dako, Produktionsvej, Denmark) substrate solution (8 mg of OPD were dissolved in 12 ml of distilled water and 4 µl H2O2 prior to use) were added to each well. After 10 min, the color development reaction was stopped by adding 50 µl of 2N sulfuric acid and the color intensity was read at 490nm. The cut off for these assays was 2 standard deviation plus mean of the negative sera. Relative sensitivity and specificity were calculated as described by Aubert et al. (5)

Results

In order to determine cut off, purified rec-SAG1 protein was coated in the IgM rec-ELISA and tested with 20 serum samples that were negative for Toxplasma IgG and IgM antibodies. The assay cut off was 2SD from the mean of negative population (mean=0.27, SD=0.104, cut off =0.478) (Fig. 1).

The immunoreactivity of rec-SAG1 was determined for 30 Toxplasma IgM-positive sera and 40 Toxplasma IgM and IgG negative sera, the results were summarized in Table 1.

Table 1: Comparison of rec-ELISA and com-ELISA in detection of IgM antibodies to T. gondii

|                  | IgM com-ELISA | Positive | Negative | Total |
|------------------|--------------|----------|----------|-------|
| *IgM rec-ELISA   | Total        | 24       | 4        | 28    |
| Positive         | 6            | 36       | 42       |
| Negative         | 30           | 40       | 70       |

* rec-SAG1 was used as antigen

The sensitivity and specificity of designated rec-ELISA in comparison to the results obtained with com-ELISA was 80% (24/30) and 90% (36/40) respectively.

Discussion

To date, many studies have been done to evaluate the ability of recombinant antigens (r-antigens) to bind T. gondii-specific antibodies (5, 12-15). Using recombinant antigens allow more precise standardization of the tests and allow designing new assays that can easily distinguish acute from chronic infection. In general, only a few reports explored the diagnostic utility of IgM rec-ELISA especially employing rec-SAG1 (8, 13 and 15).

SAG1 has been proven to be a valuable diagnostic tool, induces an intense immune response (11) and was conserved in many strains of T. gondii (16). Most of the time, detection of Toxplasma-specific IgM could confirm acute infection. Therefore in the present study, we investigated IgM specific Toxplasma antibodies directed against rec-SAG1.

There are contradictory opinions about diagnostic utility of rec-SAG1 for T. gondii-specific IgM antibody. Aubert et al. (5) reported that the p30 antigen of Toxplasma was recognized only 7 sera from 89 serum samples with a serological profile consistent with an acute Tox-
oplasmosis. In this experience, IgM assay with rec-SAG1 antigen in regarding to Aubert studies was relatively display a good performance, and could diagnose 80% of the infected patients (24/30). In another study that was carried in children at risk of congenital infection, ROC curves for the IgM capture immunoassay using the rec-SAG1 shows the best performance, in contrast to employ MIC2a, MIC2b and MIC3 antigens. The rec-SAG1 could detect 23 from 35 sera of infected infants (66%) (8); in comparison, we could get better results. There are some explanations for these well-known differences: Most important of them, may be the variant presentation of this very complex molecule epitopes that was occurred in the preparation in different studies (17). As SAG1 is a highly conformational antigen and frequently expression in E. coli is in an insoluble form, therefore lose its immunoreactivity owing to incorrect folding (18, 19).

In the present study, rec-SAG1 as a soluble form of the fusion protein was expressed by using pET32a expression vector. Consequently, the constructed vector and the optimized expression situations, could improve diagnostic ability of rec-SAG1. In spite of these differences, our findings were supported the results of Harning et al. opinion that rec-SAG1 is an appropriate marker for use in diagnostic systems to distinguish anti SAG1-specific IgG and IgM antibodies (13).

Furthermore, we believed that many more samples have to be examined to confirm these results.

Conclusion

It seems that rec-SAG1 could be a good marker for detection of anti Toxoplasma-specific IgM and diagnosis of acute infection, especially if it is used in combination with other tests, like IgG avidity.

Acknowledgement

This paper is prepared from Nahid Jalallou PhD thesis. The authors declare that there is no conflict of interest.

References

1. Pinion JM, Chemla C, Villena I, Foudrinier F, Aubert D, Puygauthier-Toubas D, et al. Early neonatal diagnosis of congenital toxoplasmosis: value of comparative enzyme-linked immunofiltration assay immunological profiles and anti-Toxoplasma gondii immunoglobulin M (IgM) or IgA immunocapture and implications for post-natal therapeutic strategies. J Clin Microbiol. 1996; 34:579-83.

2. Luft BJ, Brooks RJ, Couley FK, McCabe RE, Remington JS. Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. J Am Med Assoc. 1984; 252:913-7.

3. Hofgartner WT, Swanzy SR, Bacina RM, Condon J, Gupta M, Matlock PE, et al. Detection of immunoglobulin G (IgG) and IgM antibodies to Toxoplasma gondii: evaluation of four commercial immunoassay systems. J Clin Microbiol. 1997; 35:3313-5.

4. Wilson M, Remington JS, Clavet C, Varney G, Press C, ware D. Evaluation of six commercial kits for the detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA toxoplasmosis Ad Hoc Working Group. J Clin Microbiol. 1997; 35:3112-5.

5. Aubert D, Maine GT, Villena I, Hunt JC, Howard I, Sheu M, et al. Recombinant antigens to detect Toxoplasma gondii-specific Immunoglobulin G and Immunoglobulin M in Human Sera by enzyme immunoassay. J Clin Microbiol. 2000; 38:1144-50.

6. Hartari S, Kusumawati A, Wuryastuti H, Widadatur truc JS. Primary structure of mature SAG1 gene of an Indonesian Toxoplasma gondii and comparison with other strains. J Vet Sci. 2006; 7:263-70.

7. Handman E, Goding, JW, Remington JS. Detection and characterization of mem-

Available at: http://ijpa.tums.ac.ir
brane antigens of *Toxoplasma gondii*. J Immunol. 1980; 124:2578-83.
8. Erlich H, Rodgers G, Voilancourt P, Araujo F, & Remington J. Identification of an antigen-specific immunoglobulin M antibody associated with acute Toxoplasma infection. Infect Immun. 1983; 41:683-690.
9. Buffolano W, Beghetto E, Del Pezzo M, Spadoni A, Di Cristina M, Petersen E, et al. Use of recombinant antigens for early postnatal diagnosis of congenital toxoplasmosis. J Clin Microbiol. 2005; 43:5916-24.
10. Kazemi B, Bandehpour M, Maghen L, Solgi GH. Gene cloning of 30 kDa *Toxoplasma gondii* tachyzoites surface antigen (SAG1). Iranian J Parasitol. 2007; 2:1-8.
11. Jalalou N, Bandehpour M, Khazan H, Haghhighi A, Abdollahi SH, Kazemi B. Recombinant SAG1 antigen to detect *Toxoplasma gondii* specific immunoglobulin G in human sera by ELISA test. Iranian J Parasitol. 2010; 5:1-9.
12. Pietkiewicz H, Hiszczynska-Sawicka E, Kur J, Petersen E, Nielsen HV, Stankiewicz M, et al. Usefulness of *Toxoplasma gondii*-specific recombinant antigens in serodiagnosis of human toxoplasmosis. J Clin Microbiol. 2004; 42:1779-81.
13. Harning D, Spenter J, Metsis A, Vuust J, Petersen E. Recombinant *Toxoplasma gondii* surface antigen I (P30) expressed in Escherichia coli is recognized by human Toxoplasma-specific immunoglobulin M (IgM) and IgG antibodies. Clin Diagn Lab Immunol. 1996; 3:355-7.
14. Nigro M, Gutierre A, Hoffer AM, Clemente M, Kaufer F, Carral L. Evaluation of *Toxoplasma gondii* recombinant proteins for the diagnosis of recently acquired toxoplasmosis by an immunoglobulin G analysis. Diagn Microbiol Infect Dis. 2003; 47:609-13.
15. Beghetto E, Spadoni A, Bruno L, Buffolano W, Gargano NC. Chimeric antigens of *Toxoplasma gondii* toward standardization of toxoplasmosis serodiagnosis using recombinant products. J Clin Microbiol. 2006; 44:2133-40.
16. Kimbila EN, Xuan X, Huang X, Miyazawa T, Fukumoto S, Mishima M, et al. Serodiagnosis of *Toxoplasma gondii* infection in cats by enzyme-linked immunosorbent assay using recombinant SAG1. Vet Parasitol. 2001; 102:35-44.
17. Pfrepper KI, Enders G, Gohl M, Krzcal D, Hlobil H, Wassenberg D, et al. Seroreactivity to and avidity for recombinant antigens in toxoplasmosis. Clin Diagn Lab Immunol. 2005; 12:977-82.
18. Velige- Roussel F, Chardes T, Mevelec P, Brillard M, Hoebeke J, Bout D. Epitopic analysis of the *Toxoplasma gondii* major surface antigen SAG1. Mol Biochem Parasitol. 1994; 66:31-8.
19. Burg JL, Perelman D, Kasper LH, Ware PI, Boothrovd JC. Molecular analysis of the gene encoding the major surface antigen of *Toxoplasma gondii*. J Immunol. 1988; 141:3584-91.

Available at: [http://ijpa.tums.ac.ir](http://ijpa.tums.ac.ir)